Beam Therapeutics (BEAM) Change in Account Payables (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Change in Account Payables data on file, last reported at $2.2 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at $2.2 million, down 41.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (up 3.43% YoY), and the FY2025 annual result was $6.0 million, up 234.26% from the prior year.
• Change in Account Payables grew to $2.2 million in Q1 2026 per BEAM's latest filing, from $1.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $3.8 million in Q1 2025 and troughed at -$3.0 million in Q3 2023.
• A 5-year average of $285764.7 and a median of $102000.0 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 2584.31% in 2023, then jumped 656.28% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $2.9 million in 2022, then slumped by 160.97% to -$1.8 million in 2023, then surged by 68.89% to -$550000.0 in 2024, then surged by 317.09% to $1.2 million in 2025, then jumped by 85.59% to $2.2 million in 2026.
• Business Quant data shows BEAM's Change in Account Payables at $2.2 million in Q1 2026, $1.2 million in Q4 2025, and -$1.6 million in Q3 2025.